Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.

Khajehdehi P, Pakfetrat M, Javidnia K, Azad F, Malekmakan L, Nasab MH, Dehghanzadeh G.

Scand J Urol Nephrol. 2011 Nov;45(5):365-70. doi: 10.3109/00365599.2011.585622. Epub 2011 May 31.

PMID:
21627399
2.

Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study.

Khajehdehi P, Zanjaninejad B, Aflaki E, Nazarinia M, Azad F, Malekmakan L, Dehghanzadeh GR.

J Ren Nutr. 2012 Jan;22(1):50-7. doi: 10.1053/j.jrn.2011.03.002. Epub 2011 Jul 13.

PMID:
21742514
3.
4.

Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.

Fallahzadeh MK, Dormanesh B, Sagheb MM, Roozbeh J, Vessal G, Pakfetrat M, Daneshbod Y, Kamali-Sarvestani E, Lankarani KB.

Am J Kidney Dis. 2012 Dec;60(6):896-903. doi: 10.1053/j.ajkd.2012.06.005. Epub 2012 Jul 7.

PMID:
22770926
5.

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

Freedman BI, Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS.

Control Clin Trials. 1999 Oct;20(5):493-510.

PMID:
10503809
6.

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

Ann Intern Med. 2003 Apr 1;138(7):542-9.

PMID:
12667024
7.
8.
9.

Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.

Praga M, Andrade CF, Luño J, Arias M, Poveda R, Mora J, Prat MV, Rivera F, Galceran JM, Ara JM, Aguirre R, Bernis C, Marín R, Campistol JM.

Nephrol Dial Transplant. 2003 Sep;18(9):1806-13.

10.

[Cytokines in noninvasive diagnostics of diabetic nephropathy progression].

Senatorski G, Paczek L, Kropiewnicka E, Bartłomiejczyk I.

Pol Merkur Lekarski. 2002 Nov;13 Suppl 1:28-32. Polish.

PMID:
12621778
11.

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.

PMID:
14586737
12.

Activation of transforming growth factor-beta1 in diabetic kidney disease.

Hellmich B, Schellner M, Schatz H, Pfeiffer A.

Metabolism. 2000 Mar;49(3):353-9.

PMID:
10726914
13.

Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.

Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ.

Am J Kidney Dis. 2012 Jan;59(1):75-83. doi: 10.1053/j.ajkd.2011.09.017. Epub 2011 Nov 3.

PMID:
22051245
14.

Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus.

Cha DR, Kim IS, Kang YS, Han SY, Han KH, Shin C, Ji YH, Kim NH.

Diabet Med. 2005 Jan;22(1):14-20.

PMID:
15606685
15.

Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients.

Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S.

Iran J Kidney Dis. 2010 Apr;4(2):128-32.

16.

Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients.

Malekshahi Moghadam A, Saedisomeolia A, Djalali M, Djazayery A, Pooya S, Sojoudi F.

Singapore Med J. 2012 Sep;53(9):615-9.

17.

Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy.

Ha SW, Kim HJ, Bae JS, Jeong GH, Chung SC, Kim JG, Park SH, Kim YL, Kam S, Kim IS, Kim BW.

Diabetes Res Clin Pract. 2004 Aug;65(2):167-73.

PMID:
15223229
18.

Clinical evaluation of the effect of daio (rhei rhizoma) on the progression of diabetic nephropathy with overt proteinuria.

Goto H, Shimada Y, Tanikawa K, Sato S, Hikiami H, Sekiya N, Terasawa K.

Am J Chin Med. 2003;31(2):267-75.

PMID:
12856865
19.

[Urine TGF-beta1 concentration in patients with type II diabetes mellitus--prognostic values].

Paczek L, Kropiewnicka HE, Senatorski G, Bartłomiejczyk I.

Pol Arch Med Wewn. 2002 Aug;108(2):745-52. Polish.

PMID:
12476894
20.

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.

N Engl J Med. 2001 Sep 20;345(12):861-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk